
WilmerHale Represents Karyopharm in Agreement with Biogen to Acquire KPT-350

JANUARY 26, 2018

On January 25, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its entry into an agreement for Biogen to acquire Karyopharm's investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions. KPT-350 is a novel therapeutic candidate that works by inhibiting XPO1, resulting in reductions in inflammation and neurotoxicity, as well as increasing neuroprotective responses.

The WilmerHale team representing Karyopharm in this deal included [Steve Singer](#) and [Andrew Bonnes](#).

The full press release can be found at www.karyopharm.com.